"small cell lung cancer" trang 12 - tải miễn phí từ tailieunhanh
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
7    75    1
Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies

Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies
10    75    1
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report
4    67    1
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
8    74    1
Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2

Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2
10    51    1
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
12    76    1
Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: A multiinstitutional study of 61 subjects

Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: A multiinstitutional study of 61 subjects
11    35    1
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
12    60    1
Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Distribution and prognosis of uncommon metastases from non-small cell lung cancer
6    57    1
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib
10    75    1
Cerebral infarction in advanced non-small cell lung cancer: A case control study

Cerebral infarction in advanced non-small cell lung cancer: A case control study
7    35    1
Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy
6    50    1
Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
10    59    1
Randomized phase III trial of amrubicin/ cisplatin versus etoposide/cisplatin as firstline treatment for extensive small-cell lung cancer

Randomized phase III trial of amrubicin/ cisplatin versus etoposide/cisplatin as firstline treatment for extensive small-cell lung cancer
8    60    1
Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: A meta-analysis

Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: A meta-analysis
10    36    1
Accelerated hypofractionated threedimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial

Accelerated hypofractionated threedimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial
13    42    1
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer

Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
8    45    1
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer
9    45    1
Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014
7    42    1
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFRmutated and -wildtype non-small cell lung cancer cells

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFRmutated and -wildtype non-small cell lung cancer cells
10    57    1